Dr. Miller has over 20 years of experience developing and launching products in the life science and high technology industries. He previously held the position of Chief Operating Officer at ProterixBio and was General Manager of the Boston site.
Prior to ProterixBio, he held the position of VP of Product Development and Operations as BioScale. He had joined BioScale soon after its founding and led product development for the company’s first product, an automated immunoassay platform utilizing a unique non-optical detection method based on MEMS technology. As VP of Product Development, he managed a multi-disciplinary team of scientists and engineers covering instrumentation, software, consumables and assay development. He led the transition of the product into manufacturing and subsequently took on additional operations responsibilities, including field support, manufacturing and facilities.
Prior to BioScale, Dr. Miller held several product development leadership positions at Axsun Technologies, a company producing optical subsystems for telecommunications and medical device markets. His responsibilities spanned the phases of early prototype development, system qualification, and manufacturing scale-up.
Prior to Axsun, he was a Principal Engineer at Physical Sciences Inc., where he worked on instrumentation and control devices for aerospace applications. While at PSI, he initiated a new business area focused on MEMS technology, winning multiple research grants to support the development of multiple novel devices.
Dr. Miller earned a B.S. in Mechanical Engineering from the Rensselaer Polytechnic Institute, and an M.S. and Ph.D. in Mechanical Engineering from Stanford University. He is inventor or co-inventor on over 25 issued patents with an additional 20 pending patent applications.
Prior to joining ProterixBio, Brett Masters served as VP of Engineering at Midé Technology Corporation. Dr. Masters joined Midé in early 1997 and the role of VP of Engineering in 1998.
Dr. Masters’ educational background includes a Doctor of Science, a Master of Science, and a Bachelor of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. Prior to this, Dr. Masters attended the University of Auckland in his homeland of New Zealand.
Dr. Masters has received several awards including the NASA OAST “Commendation for Technology Excellence” for the Middeck 0-Gravity Dynamics Experiment as well as the 1994 ASME Structures and Materials Award for work presented on “Global Structure Modeling Using Force-State Component Identification”. He also won the James Mean Memorial Award (MIT) for outstanding contribution in the design of a high-flying aircraft for sampling of ozone in the Antarctic Circle as well as the Luis de Florez Award (MIT) for design ingenuity in developing, building and testing a v-shaped hydrofoil for windsurfing.
Dr. Colón brings over 25 years’ experience in biopharma, genomics, diagnostics, health care, drug delivery and industrial biotechnology.
In addition to her role at ProterixBio, she is President and CEO at InCarda Therapeutics, a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. She also serves on the board of CareDx (NASDAQ:CDNA), and previously served on the boards of Paradigm Diagnostics (acquired by Exact Sciences (NASDAQ:EXAS), PerceptiMed and Cocoon Biotech, and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.
Previously, she was founding President of the Industrial Products Division and Senior Vice President at Intrexon Corporation (NYSE:XON) where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals and was a key contributor to the company’s $100M Series E raise.
Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences (Nasdaq:GILD), where she was responsible for global execution of clinical trials. At Gilead, she also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix (acquired by ThermoFisher (NYSE:TMO), where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics.
Earlier in her career, Grace was a consultant at McKinsey & Company, where she served clients in healthcare, high tech, consumer goods and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of multiple NIH training grants. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Charlie is a seasoned financial professional with experience growing companies in fast-paced environments, improving financial performance of troubled enterprises and structuring complex transactions. His areas of expertise include design and implementation of accounting systems, budgets, forecasts and management reporting tools, capital fundraising, expense management and executing business plans to profitability.
Charlie was the Chief Financial Officer of The Merallis Company, a technology services firm located in Rocky Hill, CT, where he managed all aspects of accounting, finance and capital fundraising. Charlie defined financial reporting structures across this 90-member organization into 8 key functional departments to improve autonomy and fiscal efficiency. He revised the corporate financial plan and reduced projected expenses by 30% while maintaining expected revenue growth. Charlie also negotiated and managed all aspects of $9,500,000 in equity capital fund-raising to finance national sales and marketing initiatives.
Prior to Merallis, Charlie was a founding management member of PQC, Inc., a management services company that raised $50M in private capital, grew to 1,200 employees in 3 states and $80 million in revenue. As a Vice President at PQC, Charlie managed various aspects of finance and operations for the Company.
Charlie also founded Medical Claims Management (MCM), a practice reimbursement management and consulting firm focused on profitability improvement and operations management. MCM achieved profitability within the first 12 months of operations with $10M of revenues under management. Charlie curtailed his day-to-day involvement in this enterprise to join the founding management team of PQC and ultimately sold his interests in MCM.
Earlier in his career, Charlie worked as a Senior Consultant for Price Waterhouse and as Senior Accountant for Deloitte & Touche. He is a CPA, has a B.S. in Accountancy an A.S. in Management from Bentley College and an M.M. in Finance and Business Policy from the J.L. Kellogg School at Northwestern University. Charlie currently resides in Needham, MA with his wife and two children.